ID   ACY1_HUMAN              Reviewed;         408 AA.
AC   Q03154; C9J6I6; C9J9D8; C9JWD4;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   12-APR-2017, entry version 174.
DE   RecName: Full=Aminoacylase-1;
DE            Short=ACY-1;
DE            EC=3.5.1.14;
DE   AltName: Full=N-acyl-L-amino-acid amidohydrolase;
GN   Name=ACY1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8357837; DOI=10.1016/0167-4781(93)90116-U;
RA   Mitta M., Kato I., Tsunasawa S.;
RT   "The nucleotide sequence of human aminoacylase-1.";
RL   Biochim. Biophys. Acta 1174:201-203(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8394326;
RA   Cook R.M., Burke B.J., Buchhagen D.L., Minna J.D., Miller Y.E.;
RT   "Human aminoacylase-1. Cloning, sequence, and expression analysis of a
RT   chromosome 3p21 gene inactivated in small cell lung cancer.";
RL   J. Biol. Chem. 268:17010-17017(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Iwaki K., Tanaka Y., Ohta T., Fukuda S., Kurimoto M.;
RL   Submitted (JUN-1993) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) IN COMPLEX WITH ZINC IONS,
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, ACTIVE SITE, AND
RP   MUTAGENESIS OF HIS-80; ASP-113; GLU-147; GLU-148; GLU-175; HIS-206 AND
RP   HIS-373.
RX   PubMed=12933810; DOI=10.1074/jbc.M304233200;
RA   Lindner H.A., Lunin V.V., Alary A., Hecker R., Cygler M., Menard R.;
RT   "Essential roles of zinc ligation and enzyme dimerization for
RT   catalysis in the aminoacylase-1/M20 family.";
RL   J. Biol. Chem. 278:44496-44504(2003).
RN   [10]
RP   VARIANT ACY1D CYS-353.
RX   PubMed=16274666; DOI=10.1016/j.bbrc.2005.10.126;
RA   Van Coster R.N., Gerlo E.A., Giardina T.G., Engelke U.F., Smet J.E.,
RA   De Praeter C.M., Meersschaut V.A., De Meirleir L.J., Seneca S.H.,
RA   Devreese B., Leroy J.G., Herga S., Perrier J.P., Wevers R.A.,
RA   Lissens W.;
RT   "Aminoacylase I deficiency: a novel inborn error of metabolism.";
RL   Biochem. Biophys. Res. Commun. 338:1322-1326(2005).
RN   [11]
RP   VARIANTS ACY1D ASP-233 AND CYS-353, AND TISSUE SPECIFICITY.
RX   PubMed=16465618; DOI=10.1086/500563;
RA   Sass J.O., Mohr V., Olbrich H., Engelke U., Horvath J., Fliegauf M.,
RA   Loges N.T., Schweitzer-Krantz S., Moebus R., Weiler P., Kispert A.,
RA   Superti-Furga A., Wevers R.A., Omran H.;
RT   "Mutations in ACY1, the gene encoding aminoacylase 1, cause a novel
RT   inborn error of metabolism.";
RL   Am. J. Hum. Genet. 78:401-409(2006).
RN   [12]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-381.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [13]
RP   VARIANTS ACY1D TRP-197; CYS-353 AND HIS-393.
RX   PubMed=17562838; DOI=10.1212/01.wnl.0000264933.56204.e8;
RA   Sass J.O., Olbrich H., Mohr V., Hart C., Woldseth B., Krywawych S.,
RA   Bjurulf B., Lakhani P.K., Buchdahl R.M., Omran H.;
RT   "Neurological findings in aminoacylase 1 deficiency.";
RL   Neurology 68:2151-2153(2007).
RN   [14]
RP   VARIANTS ACY1D GLN-378; TRP-378 AND CYS-386, AND CHARACTERIZATION OF
RP   VARIANTS ACY1D TRP-197; ASP-233; CYS-353; TRP-378 AND CYS-386.
RX   PubMed=21414403; DOI=10.1016/j.bbadis.2011.03.005;
RA   Sommer A., Christensen E., Schwenger S., Seul R., Haas D., Olbrich H.,
RA   Omran H., Sass J.O.;
RT   "The molecular basis of aminoacylase 1 deficiency.";
RL   Biochim. Biophys. Acta 1812:685-690(2011).
CC   -!- FUNCTION: Involved in the hydrolysis of N-acylated or N-acetylated
CC       amino acids (except L-aspartate). {ECO:0000269|PubMed:12933810}.
CC   -!- CATALYTIC ACTIVITY: An N-acyl-aliphatic-L-amino acid + H(2)O = an
CC       aliphatic L-amino acid + a carboxylate.
CC       {ECO:0000269|PubMed:12933810}.
CC   -!- CATALYTIC ACTIVITY: An N-acetyl-L-cysteine-S-conjugate + H(2)O =
CC       an L-cysteine-S-conjugate + acetate.
CC       {ECO:0000269|PubMed:12933810}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:12933810};
CC       Note=Binds 2 Zn(2+) ions per subunit.
CC       {ECO:0000269|PubMed:12933810};
CC   -!- SUBUNIT: Homodimer. Interacts with SPHK1 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-742064, EBI-742064;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-742064, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q03154-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q03154-2; Sequence=VSP_046877;
CC         Note=Gene prediction based on EST data.;
CC       Name=3;
CC         IsoId=Q03154-3; Sequence=VSP_046878;
CC         Note=Gene prediction based on EST data.;
CC       Name=4;
CC         IsoId=Q03154-4; Sequence=VSP_046876;
CC         Note=Gene prediction based on EST data.;
CC   -!- TISSUE SPECIFICITY: Expression is highest in kidney, strong in
CC       brain and weaker in placenta and spleen.
CC       {ECO:0000269|PubMed:16465618}.
CC   -!- DISEASE: Aminoacylase-1 deficiency (ACY1D) [MIM:609924]: An
CC       enzymatic deficiency resulting in encephalopathy, unspecific
CC       psychomotor delay, psychomotor delay with atrophy of the vermis
CC       and syringomyelia, marked muscular hypotonia or normal clinical
CC       features. Epileptic seizures are a frequent feature. All affected
CC       individuals exhibit markedly increased urinary excretion of
CC       several N-acetylated amino acids. {ECO:0000269|PubMed:16274666,
CC       ECO:0000269|PubMed:16465618, ECO:0000269|PubMed:17562838,
CC       ECO:0000269|PubMed:21414403}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase M20A family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07548; AAA02852.1; -; mRNA.
DR   EMBL; D14524; BAA03397.1; -; mRNA.
DR   EMBL; D16307; BAA03814.1; -; mRNA.
DR   EMBL; AC115284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000545; AAH00545.1; -; mRNA.
DR   EMBL; BC003023; AAH03023.1; -; mRNA.
DR   EMBL; BC014112; AAH14112.1; -; mRNA.
DR   CCDS; CCDS2844.1; -. [Q03154-1]
DR   CCDS; CCDS56261.1; -. [Q03154-2]
DR   CCDS; CCDS56262.1; -. [Q03154-3]
DR   CCDS; CCDS56263.1; -. [Q03154-4]
DR   PIR; A47488; A47488.
DR   RefSeq; NP_000657.1; NM_000666.2. [Q03154-1]
DR   RefSeq; NP_001185824.1; NM_001198895.1. [Q03154-1]
DR   RefSeq; NP_001185825.1; NM_001198896.1. [Q03154-2]
DR   RefSeq; NP_001185826.1; NM_001198897.1. [Q03154-3]
DR   RefSeq; NP_001185827.1; NM_001198898.1. [Q03154-4]
DR   UniGene; Hs.334707; -.
DR   PDB; 1Q7L; X-ray; 1.40 A; A/C=1-198, B/D=321-408.
DR   PDBsum; 1Q7L; -.
DR   ProteinModelPortal; Q03154; -.
DR   SMR; Q03154; -.
DR   BioGrid; 106610; 23.
DR   IntAct; Q03154; 17.
DR   MINT; MINT-4999851; -.
DR   STRING; 9606.ENSP00000384296; -.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   MEROPS; M20.973; -.
DR   iPTMnet; Q03154; -.
DR   PhosphoSitePlus; Q03154; -.
DR   BioMuta; ACY1; -.
DR   DMDM; 461466; -.
DR   REPRODUCTION-2DPAGE; IPI00009268; -.
DR   EPD; Q03154; -.
DR   PaxDb; Q03154; -.
DR   PeptideAtlas; Q03154; -.
DR   PRIDE; Q03154; -.
DR   DNASU; 95; -.
DR   Ensembl; ENST00000404366; ENSP00000384296; ENSG00000243989. [Q03154-1]
DR   Ensembl; ENST00000476351; ENSP00000417056; ENSG00000243989. [Q03154-4]
DR   Ensembl; ENST00000476854; ENSP00000419262; ENSG00000243989. [Q03154-3]
DR   Ensembl; ENST00000494103; ENSP00000417618; ENSG00000243989. [Q03154-2]
DR   Ensembl; ENST00000636358; ENSP00000490149; ENSG00000243989. [Q03154-1]
DR   GeneID; 95; -.
DR   KEGG; hsa:95; -.
DR   UCSC; uc021wzb.2; human. [Q03154-1]
DR   CTD; 95; -.
DR   DisGeNET; 95; -.
DR   GeneCards; ACY1; -.
DR   HGNC; HGNC:177; ACY1.
DR   HPA; CAB003695; -.
DR   HPA; HPA036174; -.
DR   HPA; HPA036175; -.
DR   MalaCards; ACY1; -.
DR   MIM; 104620; gene.
DR   MIM; 609924; phenotype.
DR   neXtProt; NX_Q03154; -.
DR   OpenTargets; ENSG00000243989; -.
DR   Orphanet; 137754; Neurological conditions associated with aminoacylase 1 deficiency.
DR   PharmGKB; PA24497; -.
DR   eggNOG; KOG2275; Eukaryota.
DR   eggNOG; COG0624; LUCA.
DR   GeneTree; ENSGT00870000136518; -.
DR   HOGENOM; HOG000021196; -.
DR   HOVERGEN; HBG000982; -.
DR   InParanoid; Q03154; -.
DR   KO; K14677; -.
DR   OrthoDB; EOG091G0A7U; -.
DR   PhylomeDB; Q03154; -.
DR   TreeFam; TF313693; -.
DR   BioCyc; MetaCyc:HS03800-MONOMER; -.
DR   BRENDA; 3.5.1.14; 2681.
DR   Reactome; R-HSA-5423646; Aflatoxin activation and detoxification.
DR   SABIO-RK; Q03154; -.
DR   ChiTaRS; ACY1; human.
DR   EvolutionaryTrace; Q03154; -.
DR   GeneWiki; ACY1; -.
DR   GenomeRNAi; 95; -.
DR   PRO; PR:Q03154; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000243989; -.
DR   CleanEx; HS_ACY1; -.
DR   ExpressionAtlas; Q03154; baseline and differential.
DR   Genevisible; Q03154; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0004046; F:aminoacylase activity; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008237; F:metallopeptidase activity; IEA:InterPro.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; IEA:InterPro.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   CDD; cd05646; M20_AcylaseI_like; 1.
DR   InterPro; IPR001261; ArgE/DapE_CS.
DR   InterPro; IPR010159; N-acyl_aa_amidohydrolase.
DR   InterPro; IPR002933; Peptidase_M20.
DR   InterPro; IPR011650; Peptidase_M20_dimer.
DR   Pfam; PF07687; M20_dimer; 1.
DR   Pfam; PF01546; Peptidase_M20; 1.
DR   PIRSF; PIRSF036696; ACY-1; 1.
DR   SUPFAM; SSF55031; SSF55031; 1.
DR   TIGRFAMs; TIGR01880; Ac-peptdase-euk; 1.
DR   PROSITE; PS00758; ARGE_DAPE_CPG2_1; 1.
DR   PROSITE; PS00759; ARGE_DAPE_CPG2_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; Hydrolase; Metal-binding; Polymorphism;
KW   Reference proteome; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P37111}.
FT   CHAIN         2    408       Aminoacylase-1.
FT                                /FTId=PRO_0000185236.
FT   ACT_SITE     82     82       {ECO:0000250}.
FT   ACT_SITE    147    147       Proton acceptor.
FT                                {ECO:0000269|PubMed:12933810}.
FT   METAL        80     80       Zinc 1.
FT   METAL       113    113       Zinc 1.
FT   METAL       113    113       Zinc 2.
FT   METAL       148    148       Zinc 2.
FT   METAL       175    175       Zinc 1.
FT   METAL       373    373       Zinc 2.
FT   VAR_SEQ      32     66       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_046876.
FT   VAR_SEQ     103    174       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_046877.
FT   VAR_SEQ     220    284       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_046878.
FT   VARIANT     179    179       N -> S (in dbSNP:rs887540).
FT                                /FTId=VAR_051805.
FT   VARIANT     197    197       R -> W (in ACY1D; loss of activity;
FT                                dbSNP:rs121912700).
FT                                {ECO:0000269|PubMed:17562838,
FT                                ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_043113.
FT   VARIANT     233    233       E -> D (in ACY1D; loss of activity;
FT                                dbSNP:rs121912699).
FT                                {ECO:0000269|PubMed:16465618,
FT                                ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_026104.
FT   VARIANT     353    353       R -> C (in ACY1D; loss of activity;
FT                                dbSNP:rs121912698).
FT                                {ECO:0000269|PubMed:16274666,
FT                                ECO:0000269|PubMed:16465618,
FT                                ECO:0000269|PubMed:17562838,
FT                                ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_026105.
FT   VARIANT     378    378       R -> Q (in ACY1D; dbSNP:rs150480963).
FT                                {ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_065562.
FT   VARIANT     378    378       R -> W (in ACY1D; slightly reduced
FT                                activity; dbSNP:rs148346337).
FT                                {ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_065563.
FT   VARIANT     381    381       E -> D (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036076.
FT   VARIANT     386    386       R -> C (in ACY1D; loss of activity;
FT                                dbSNP:rs2229152).
FT                                {ECO:0000269|PubMed:21414403}.
FT                                /FTId=VAR_020452.
FT   VARIANT     393    393       R -> H (in ACY1D; dbSNP:rs121912701).
FT                                {ECO:0000269|PubMed:17562838}.
FT                                /FTId=VAR_043114.
FT   MUTAGEN      80     80       H->A: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     113    113       D->A: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     147    147       E->A,Q: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     147    147       E->D: Decreased protein stability. Loss
FT                                of enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     148    148       E->A: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     175    175       E->A: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     206    206       H->N: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   MUTAGEN     373    373       H->A: Almost abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12933810}.
FT   HELIX        11     20       {ECO:0000244|PDB:1Q7L}.
FT   HELIX        31     45       {ECO:0000244|PDB:1Q7L}.
FT   STRAND       48     55       {ECO:0000244|PDB:1Q7L}.
FT   STRAND       58     65       {ECO:0000244|PDB:1Q7L}.
FT   STRAND       74     80       {ECO:0000244|PDB:1Q7L}.
FT   HELIX        88     90       {ECO:0000244|PDB:1Q7L}.
FT   TURN         95     97       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      104    107       {ECO:0000244|PDB:1Q7L}.
FT   TURN        109    114       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       115    130       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      139    145       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       147    149       {ECO:0000244|PDB:1Q7L}.
FT   TURN        152    154       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       155    158       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       162    165       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      169    174       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      180    188       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       194    196       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       322    333       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      338    342       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       348    354       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      359    362       {ECO:0000244|PDB:1Q7L}.
FT   STRAND      378    380       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       381    399       {ECO:0000244|PDB:1Q7L}.
FT   HELIX       405    407       {ECO:0000244|PDB:1Q7L}.
SQ   SEQUENCE   408 AA;  45885 MW;  293350CD7759826C CRC64;
     MTSKGPEEEH PSVTLFRQYL RIRTVQPKPD YGAAVAFFEE TARQLGLGCQ KVEVAPGYVV
     TVLTWPGTNP TLSSILLNSH TDVVPVFKEH WSHDPFEAFK DSEGYIYARG AQDMKCVSIQ
     YLEAVRRLKV EGHRFPRTIH MTFVPDEEVG GHQGMELFVQ RPEFHALRAG FALDEGIANP
     TDAFTVFYSE RSPWWVRVTS TGRPGHASRF MEDTAAEKLH KVVNSILAFR EKEWQRLQSN
     PHLKEGSVTS VNLTKLEGGV AYNVIPATMS ASFDFRVAPD VDFKAFEEQL QSWCQAAGEG
     VTLEFAQKWM HPQVTPTDDS NPWWAAFSRV CKDMNLTLEP EIMPAATDNR YIRAVGVPAL
     GFSPMNRTPV LLHDHDERLH EAVFLRGVDI YTRLLPALAS VPALPSDS
//
